Generating Functional and Highly Proliferative Melanocytes Derived from Human Pluripotent Stem Cells: A Promising Tool for Biotherapeutic Approaches to Treat Skin Pigmentation Disorders

Int J Mol Sci. 2023 Mar 29;24(7):6398. doi: 10.3390/ijms24076398.

Abstract

Melanocytes are essential for skin homeostasis and protection, and their loss or misfunction leads to a wide spectrum of diseases. Cell therapy utilizing autologous melanocytes has been used for years as an adjunct treatment for hypopigmentary disorders such as vitiligo. However, these approaches are hindered by the poor proliferative capacity of melanocytes obtained from skin biopsies. Recent advances in the field of human pluripotent stem cells have fueled the prospect of generating melanocytes. Here, we have developed a well-characterized method to produce a pure and homogenous population of functional and proliferative melanocytes. The genetic stability and potential transformation of melanocytes from pluripotent stem cells have been evaluated over time during the in vitro culture process. Thanks to transcriptomic analysis, the molecular signatures all along the differentiation protocol have been characterized, providing a solid basis for standardizing the protocol. Altogether, our results promise meaningful, broadly applicable, and longer-lasting advances for pigmentation disorders and open perspectives for innovative biotherapies for pigment disorders.

Keywords: human pluripotent stem cell; pigmentation-related skin disorders; skin regeneration.

MeSH terms

  • Humans
  • Melanocytes / pathology
  • Pigmentation Disorders* / therapy
  • Pluripotent Stem Cells*
  • Skin / pathology
  • Skin Pigmentation
  • Vitiligo* / pathology
  • Vitiligo* / therapy

Grants and funding

I-STEM is part of the Biotherapies Institute for Rare Diseases supported by the Association Française contre les Myopathies (AFM)-Téléthon, INSERM and Université d’Evry Val d’Essonne/Paris Saclay. This work was supported by grants from Laboratoire d’Excellence Revive (Investissement d’Avenir; ANR-10-LABX-73) and the program “investissement d’avenir” of INGESTEM and GENOPOLE.